Aarti Drugs Limited has informed the Exchange about Business Responsibility and Sustainability Report for FY 2024-25

Aarti Drugs has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 to the exchanges, as mandated under SEBI's Listing Regulations. The company is a pure-play pharmaceutical manufacturer with revenue of about ₹2,174 crore, of which APIs contribute 91%, speciality chemicals 6%, and intermediates 3%. It runs 13 plants and 2 offices across India, serves 100+ countries with exports making up roughly 35% of revenue, and employs about 2,865 people (employees plus workers). On ESG, 9 of its 11 API facilities operate on a Zero Liquid Discharge basis, it holds WHO-GMP, EU-GMP, and ISO 9001/14001/45001 certifications, and it spent 11% of R&D and 10.85% of capex on environmental and social improvements during the year. The report also flags a CGST order demanding ₹20.72 crore plus interest and penalty, against which the company has filed a writ petition and secured interim relief from the Bombay High Court.